FIELD: biotechnology.
SUBSTANCE: invention relates to the biotechnology. Invention specifically relates to a method of producing a polyvalent influenza vaccine containing HPV, where haemagglutinin, neuraminidase and M1 protein genes are obtained from strain A/California/04/2009; haemagglutinin gene is obtained from strain A/Michigan/45/2015, and neuraminidase and M1 protein genes are obtained from strain A/California/04/2009; haemagglutinin gene is obtained from strain A/Novosibirsk/01/2014, and neuraminidase and M1 protein genes are obtained from strain A/California/04/2009; haemagglutinin gene is obtained from strain A/HongKong/4801/2014, and neuraminidase and M1 protein genes are obtained from strain A/California/04/2009; haemagglutinin gene is obtained from strain B/Phuket/3073/13, and neuraminidase and M1 protein genes are obtained from strain A/California/04/2009 or haemagglutinin gene is obtained from strain B/Brisbane/60/2008, and neuraminidase and M1 protein genes are obtained from strain A/California/04/2009.
EFFECT: invention allows to obtain HPV of influenza virus having high hemagglutinating activity, the method allows increasing the antigen yield, besides, during the method implementation the vitality and high productivity of the target proteins are preserved without use of controlled expression in HPV influenza cell-producers.
3 cl, 44 dwg, 15 tbl, 7 ex
